Jones Financial Companies
UBX

Jones Financial Companies’s Unity Biotechnology UBX Stock Holding History

Jones Financial Companies’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26
Closed -$25 – 3864
2024
Q4 		$25 Hold
26
– – ﹤0.01% 3396
2024
Q3 		$38 Buy
+26
New +$38 ﹤0.01% 2998

Other funds holding UBX

FH
Financial Harvest Winter Park, Florida $242M AUM 23.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Jones Financial Companies's UBX Position: Q1 2025 in Review

Jones Financial Companies sold out of Unity Biotechnology (UBX) in Q1 2025, closing a stake of 26 shares — an estimated $25 sold.

Jones Financial Companies first reported a position in UBX in Q3 2024 and held it in 2 quarters. The position peaked at $38 in Q3 2024. 40 funds tracked by Wall St. Rank hold UBX as of Q1 2025.

  • Jones Financial Companies reported no remaining Unity Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Jones Financial Companies sold 26 Unity Biotechnology shares in Q1 2025, an estimated $25.
  • Jones Financial Companies first reported a position in Unity Biotechnology in Q3 2024 and held it in 2 quarters.
  • Jones Financial Companies's Unity Biotechnology position peaked at $38 in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2025.

Based on Jones Financial Companies's 13F filing for Q1 2025, filed 16 May 2025.